{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:47Z","timestamp":1792007747282,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Liver Disease Prevention and Treatment Research Foundation, Taiwan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12072-024-10758-3","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T01:39:15Z","timestamp":1733189955000},"page":"405-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial"],"prefix":"10.1007","volume":"19","author":[{"given":"Meng-Tzu","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Fu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Shu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chuan","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Ching","family":"Nien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"10758_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u20132224","journal-title":"Lancet"},{"key":"10758_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384","journal-title":"Hepatology"},{"key":"10758_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10758_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clinre.2011.08.001","volume":"36","author":"M Sasso","year":"2012","unstructured":"Sasso M, Miette V, Sandrin L, et al. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36:13\u201320","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10758_CR5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717\u20131730","journal-title":"Gastroenterology"},{"key":"10758_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509","journal-title":"N Engl J Med"},{"key":"10758_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2169\/internalmedicine.56.7196","volume":"56","author":"T Tosaki","year":"2017","unstructured":"Tosaki T, Kamiya H, Himeno T, et al. Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes. Intern Med. 2017;56:597\u2013604","journal-title":"Intern Med"},{"key":"10758_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u20131031","journal-title":"J Clin Endocrinol Metab"},{"key":"10758_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285\u2013292","journal-title":"Diabetes Obes Metab"},{"key":"10758_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1478-3231.2012.02820.x","volume":"32","author":"V de Ledinghen","year":"2012","unstructured":"de Ledinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911\u2013918","journal-title":"Liver Int"},{"key":"10758_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247\u2013254","journal-title":"Ann Intern Med"},{"key":"10758_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12020-022-03157-x","volume":"78","author":"A Salmi","year":"2022","unstructured":"Salmi A, di Filippo L, Ferrari C, et al. Ultrasound and FibroScan((R)) Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. Endocrine. 2022;78:262\u2013269","journal-title":"Endocrine"},{"issue":"48","key":"10758_CR13","first-page":"489","volume":"2021","author":"G Ferraioli","year":"2001","unstructured":"Ferraioli G. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason. 2001;2021(48):489\u2013495","journal-title":"J Med Ultrason"},{"key":"10758_CR14","doi-asserted-by":"publisher","first-page":"1144838","DOI":"10.3389\/fendo.2023.1144838","volume":"14","author":"P Zhou","year":"2023","unstructured":"Zhou P, Tan Y, Hao Z, et al. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1144838","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10758_CR15","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020;37:4697\u20134708","journal-title":"Adv Ther"},{"key":"10758_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/jcm9010259","volume":"9","author":"E Han","year":"2020","unstructured":"Han E, Lee YH, Lee BW, et al. Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial. J Clin Med. 2020;9:259\u2013272","journal-title":"J Clin Med"},{"key":"10758_CR17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical Trial. Diabetes Ther. 2021;12:843\u2013861","journal-title":"Diabetes Ther"},{"key":"10758_CR18","doi-asserted-by":"publisher","first-page":"1102792","DOI":"10.3389\/fphar.2023.1102792","volume":"14","author":"Y Gu","year":"2023","unstructured":"Gu Y, Sun L, Zhang W, et al. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: a GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1102792","journal-title":"Front Pharmacol"},{"key":"10758_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u2013357","journal-title":"Hepatology"},{"key":"10758_CR20","first-page":"122","volume":"82","author":"CWY Hu","year":"2020","unstructured":"Hu C WY, Xi Y, Yao X. Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Indian J Pharm Sci. 2020;82:122\u2013129","journal-title":"Indian J Pharm Sci"},{"key":"10758_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3748\/wjg.v19.i1.57","volume":"19","author":"S Zelber-Sagi","year":"2013","unstructured":"Zelber-Sagi S, Webb M, Assy N, et al. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol. 2013;19:57\u201364","journal-title":"World J Gastroenterol"},{"key":"10758_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:367\u2013378","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10758_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13457","author":"KY Cho","year":"2020","unstructured":"Cho KY, Nakamura A, Omori K, et al. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig. 2020. https:\/\/doi.org\/10.1111\/jdi.13457","journal-title":"J Diabetes Investig"},{"key":"10758_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105319","volume":"163","author":"M Simental-Mendia","year":"2021","unstructured":"Simental-Mendia M, Sanchez-Garcia A, Rodriguez-Ramirez M, et al. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021;163: 105319","journal-title":"Pharmacol Res"},{"key":"10758_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187066","volume":"12","author":"HW Lee","year":"2017","unstructured":"Lee HW, Kim KJ, Jung KS, et al. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS ONE. 2017;12: e0187066","journal-title":"PLoS ONE"},{"key":"10758_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106730","volume":"86","author":"MK ElMahdy","year":"2020","unstructured":"ElMahdy MK, Helal MG, Ebrahim TM. Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-alpha, IL-1beta, and IL-18 in rat liver. Int Immunopharmacol. 2020;86: 106730","journal-title":"Int Immunopharmacol"},{"key":"10758_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","volume":"12","author":"L Li","year":"2021","unstructured":"Li L, Li Q, Huang W, et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol. 2021;12: 589273","journal-title":"Front Pharmacol"},{"key":"10758_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116167","volume":"223","author":"Z Jin","year":"2024","unstructured":"Jin Z, Yin R, Yuan Y, et al. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRalpha-mediated synthesis of lipids and bile acids. Biochem Pharmacol. 2024;223: 116167","journal-title":"Biochem Pharmacol"},{"issue":"598\u2013607","key":"10758_CR29","volume":"152","author":"CC Park","year":"2017","unstructured":"Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(598\u2013607): e2","journal-title":"Gastroenterology"},{"key":"10758_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10758-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10758-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10758-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T01:36:15Z","timestamp":1744767375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10758-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10758"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10758-3","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Meng-Tzu Weng, Po-Jen Yang, Pan-Fu Liu, Chin-Hao Chang, Hsuan-Shu Lee, Jin-Chuan Sheu and Hsiao-Ching Nien declare that they have no conflicts of interest to disclose regarding the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Research Ethics Committee of the National Taiwan University Hospital (approval number: 202104098MIPC) and performed in accordance with the ethical standards as laid down in the Helsinki Declaration of 1975, as revised in 2008. All participants signed informed consent for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors approved the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}